{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:35:20Z","timestamp":1787726120563,"version":"build-2784847793"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["J Addict Med"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:p>In the context of the US overdose crisis, improving access to medications for opioid use disorder is urgently needed. The Canadian model of methadone treatment, whereby clinicians can prescribe methadone for opioid use disorder in office-based settings and methadone can be dispensed through community pharmacies, offers a compelling model for adoption in the US. Office-based settings in which methadone is prescribed often adopt a rapid-access model, allowing walk-in appointments and same-day initiation of methadone. Prescribing authorization requirements have been relaxed over the past 25 years to improve access to methadone. This paper summarizes the model of office-based methadone prescribing in Canada, highlighting the regulatory structures, prescribing practices, and interprofessional collaborations that enable methadone treatment in office-based settings. Potential implementation strategies for adopting office-based prescribing in the US are discussed.<\/jats:p>","DOI":"10.1097\/adm.0000000000000950","type":"journal-article","created":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T14:08:44Z","timestamp":1641996524000},"page":"499-504","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":16,"title":["Office-based Methadone Prescribing for Opioid Use Disorder: The Canadian Model"],"prefix":"10.1097","volume":"16","author":[{"given":"Robert A.","family":"Kleinman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas D.","family":"Brothers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlon","family":"Danilewitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anees","family":"Bahji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,1,11]]},"reference":[{"key":"bib1-20250526","first-page":"j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies","volume":"357","year":"2017","journal-title":"BMJ"},{"issue":"6","key":"bib2-20250526","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.drugpo.2013.05.005","article-title":"What is low threshold methadone maintenance treatment?","volume":"24","year":"2013","journal-title":"Int J Drug Policy"},{"issue":"11","key":"bib3-20250526","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1001\/jamapsychiatry.2020.1624","article-title":"Comparison of driving times to opioid treatment programs and pharmacies in the US","volume":"77","year":"2020","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"bib4-20250526","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0740-5472(03)00188-0","article-title":"Distance traveled to outpatient drug treatment and client retention","volume":"25","year":"2003","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"bib5-20250526","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/08897077.2021.1975344","article-title":"Research priorities for expanding access to methadone treatment for opioid use disorder in the United States: a National Institute on Drug Abuse Clinical Trials Network Task Force report","volume":"42","year":"2021","journal-title":"Substance Abuse"},{"issue":"6","key":"bib6-20250526","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s11606-018-4801-3","article-title":"Methadone matters: what the united states can learn from the global effort to treat opioid addiction","volume":"34","year":"2019","journal-title":"J Gen Intern Med"},{"issue":"8","key":"bib7-20250526","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1377\/hlthaff.2012.0846","article-title":"A call for evidence-based medical treatment of opioid dependence in the United States and Canada","volume":"32","year":"2013","journal-title":"Health Aff (Millwood)"},{"issue":"26","key":"bib8-20250526","doi-asserted-by":"crossref","first-page":"667","DOI":"10.15585\/mmwr.mm6526a2","article-title":"Trends in methadone distribution for pain treatment, methadone diversion, and overdose deaths \u2014 United States, 2002\u20132014","volume":"65","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"9","key":"bib9-20250526","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1176\/appi.ajp.2021.20101548","article-title":"Office-based methadone treatment for opioid use disorder and pharmacy dispensing: a scoping review","volume":"178","year":"2021","journal-title":"AJP"},{"issue":"2","key":"bib10-20250526","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2307\/3343343","article-title":"Prescriptions, power and politics: the turbulent history of methadone maintenance in Canada","volume":"21","year":"2000","journal-title":"J Public Health Policy"},{"key":"bib11-20250526","first-page":"0844562121996222","article-title":"Facilitators and barriers to nurse practitioners prescribing methadone for opioid use disorder in nova scotia: a qualitative study","year":"2021","journal-title":"Can J Nurs Res"},{"key":"bib17-20250526","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.drugalcdep.2017.05.002","article-title":"Patterns of physician prescribing for opioid maintenance treatment in Ontario, Canada in 2014","volume":"177","year":"2017","journal-title":"Drug Alcohol Depend"},{"key":"bib19-20250526","article-title":"Low Barrier Same Day Access to Opioid Agonist Treatment via Telehealth\/Telemedicine","journal-title":"Presented at: American Society for Addiction Medicine 2021 Annual Conference"},{"key":"bib20-20250526","article-title":"Registered Nurse and Registered Psychiatric Nurse Public Health Pharmacotherapy"},{"key":"bib26-20250526","article-title":"AFPC Commitment to the Joint Statement of Action to Address the Opioid Crisis in Canada","year":"2018","journal-title":"Association of Faculties of Pharmacy of Canada"},{"key":"bib27-20250526","article-title":"COVID-19 Opioid Agonist Treatment Guidance","year":"2020"},{"key":"bib28-20250526","article-title":"Telemedicine Support for Addiction Services: National Rapid Guidance Document","year":"2020","journal-title":"Canadian Research Initiative in Substance Misuse"},{"issue":"2","key":"bib30-20250526","first-page":"e95","article-title":"Patterns of methadone maintenance treatment provision in Ontario: policy success or pendulum excess?","volume":"64","year":"2018","journal-title":"Can Fam Physician"},{"key":"bib31-20250526","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jsat.2017.11.010","article-title":"Increasing diversion of methadone in Vancouver, Canada, 2005\u20132015","volume":"85","year":"2018","journal-title":"J Subst Abuse Treat"},{"key":"bib32-20250526","article-title":"Trends in the Use of Methadone, Buprenorphine, and Extended-release Naltrexone at Substance Abuse Treatment Facilities: 2003\u20132015 (Update)","journal-title":"The CBHSQ Report: August 22, 2017. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration"},{"issue":"6","key":"bib35-20250526","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/ADM.0000000000000156","article-title":"Evaluating the effectiveness of firsttime methadone maintenance therapy across northern, rural, and urban regions of Ontario, Canada","volume":"9","year":"2015","journal-title":"J Addict Med"},{"issue":"7","key":"bib36-20250526","doi-asserted-by":"crossref","first-page":"e1002625","DOI":"10.1371\/journal.pmed.1002625","article-title":"Methadone maintenance treatment and mortality in people with criminal convictions: a population-based retrospective cohort study from Canada","volume":"15","year":"2018","journal-title":"PLOS Med"},{"key":"bib37-20250526","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.drugalcdep.2015.08.037","article-title":"The impact of low-threshold methadone maintenance treatment on mortality in a Canadian setting","volume":"156","year":"2015","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"bib38-20250526","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1080\/00952990.2017.1376678","article-title":"Increasing availability of illicit and prescription opioids among people who inject drugs in a Canadian setting, 2010\u20132014","volume":"44","year":"2018","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"34","key":"bib39-20250526","doi-asserted-by":"crossref","first-page":"E967","DOI":"10.1503\/cmaj.200191","article-title":"Toxicology and prescribed medication histories among people experiencing fatal illicit drug overdose in British Columbia, Canada","volume":"192","year":"2020","journal-title":"CMAJ"},{"issue":"1","key":"bib40-20250526","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1477-7517-8-17","article-title":"Harm reduction, methadone maintenance treatment and the root causes of health and social inequities: an intersectional lens in the Canadian context","volume":"8","year":"2011","journal-title":"Harm Reduct J"},{"issue":"2","key":"bib41-20250526","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1080\/10826084.2017.1325376","article-title":"Primary care physicians\u2019 views about prescribing methadone to treat opioid use disorder","volume":"53","year":"2018","journal-title":"Subst Use Misuse"},{"key":"bib42-20250526","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1477-7517-9-20","article-title":"Physicians\u2019 attitudes towards office-based delivery of methadone maintenance therapy: results from a cross-sectional survey of Nova Scotia primary-care physicians","volume":"9","year":"2012","journal-title":"Harm Reduct J"},{"issue":"6","key":"bib43-20250526","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1016\/j.drugpo.2013.04.001","article-title":"Zoned Out:. \u201cNIMB Yism\u201d, addiction services and municipal governance in British Columbia","volume":"24","year":"2013","journal-title":"Int J Drug Policy"},{"issue":"2","key":"bib44-20250526","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.17269\/CJPH.108.5858","article-title":"Zoning out methadone and rising opioid-related deaths in Ontario: reforms and municipal government actions","volume":"108","year":"2017","journal-title":"Can J Public Health"},{"issue":"1","key":"bib45-20250526","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/jrh.12264","article-title":"Perceived barriers and facilitators to providing methadone maintenance treatment among rural community pharmacists in Southwestern Ontario","volume":"34","year":"2018","journal-title":"J Rural Health"},{"issue":"5","key":"bib46-20250526","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3109\/16066350009005592","article-title":"The expansion of methadone prescribing in Ontario, 1996\u20131998","volume":"8","year":"2000","journal-title":"Addict Res"},{"issue":"2\u20133","key":"bib47-20250526","first-page":"226","article-title":"Methadone medical maintenance: an early 21st-century perspective","volume":"34","year":"2015","journal-title":"J Addict Dis"},{"key":"bib48-20250526","doi-asserted-by":"crossref","first-page":"107968","DOI":"10.1016\/j.drugalcdep.2020.107968","article-title":"Pharmacy-based methadone dispensing and drive time to methadone treatment in five states within the United States: a cross-sectional study","volume":"211","year":"2020","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"bib49-20250526","doi-asserted-by":"crossref","first-page":"e0229239","DOI":"10.1371\/journal.pone.0229239","article-title":"Directly observed therapy for HCV with glecaprevir\/pibrentasvir alongside opioid substitution in people who inject drugs\u2014first real world data from Austria","volume":"15","year":"2020","journal-title":"PLOS One"},{"issue":"11","key":"bib50-20250526","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1007\/s11606-021-06850-1","article-title":"Rapid access to medications for opioid use disorder","volume":"36","year":"2021","journal-title":"J Gen Intern Med"}],"container-title":["Journal of Addiction Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ADM.0000000000000950","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T16:04:07Z","timestamp":1748275447000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/ADM.0000000000000950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,11]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/adm.0000000000000950","relation":{},"ISSN":["1932-0620"],"issn-type":[{"value":"1932-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1,11]]}}}